Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- VESIcare (solifenacin)
- vibegron
Interactions between your drugs
solifenacin vibegron
Applies to: VESIcare (solifenacin), vibegron
MONITOR: Concomitant use of vibegron with antimuscarinic agents used in the treatment of overactive bladder (OAB) may increase the risk of urinary retention. Urinary retention has been reported in clinical trials and in the postmarketing period with use of vibegron.
MANAGEMENT: Caution is advised if vibegron is prescribed in combination with antimuscarinic medications used for the treatment of OAB. Vibegron should be discontinued in patients who develop urinary retention.
References (1)
- (2021) "Product Information. Gemtesa (vibegron)." Urovant Sciences, Inc
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
Anticholinergics/antispasmodics
Therapeutic duplication
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category:
- VESIcare (solifenacin)
- vibegron
Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Gemtesa
Gemtesa (vibegron) is used to treat overactive bladder symptoms (OAB) in adults or men taking ...
Myrbetriq
Myrbetriq (mirabegron) is used to treat overactive bladder with symptoms of frequent or urgent ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Estrace
Estrace (estradiol) is used to treat symptoms of menopause such as hot flashes and vaginal dryness ...
Detrol
Detrol is used to treat overactive bladder symptoms of urinary frequency, urgency, and ...
Ditropan
Ditropan XL (oxybutynin extended release) is used to treat the symptoms of overactive bladder ...
Estradiol Patch
Estradiol Patch is used for atrophic urethritis, atrophic vaginitis, breast cancer, palliative ...
Vagifem
Vagifem vaginal inserts are used treat menopause symptoms such as dryness, burning, and irritation ...
Estrace Vaginal Cream
Estrace Vaginal Cream is used for atrophic urethritis, atrophic vaginitis
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.